Cernevit is indicated for adults and children over 11 years of age requiring parenteral multivitamin supplementation to help address or avoid vitamin depletion. This method of delivery is utilized when a patient’s body is unable to receive or absorb vitamins adequately through the mouth, or when oral intake is medically unsuitable or impossible.

This medication is officially designated to aid in the provision of daily multivitamin requirements when nourishment via the digestive system is compromised. The intended patient benefit is to support the maintenance of vitamin levels necessary for core metabolic processes and overall patient care. The indications focus on the supply of vitamins corresponding to daily needs when oral nutrition is contraindicated, impossible, or insufficient, such as in cases of malnutrition or malabsorption.

“The provision of micronutrients is an important factor in patient management.”

Quick Fact: Relief for Nutritional Depletion

Cernevit is officially indicated for adults and children over 11 years of age requiring multivitamin supplementation via the parenteral route.

Contraindications (Do Not Use)

Use of Cernevit is strictly contraindicated in patients with the following conditions:

• Pre-existing hypervitaminosis (excessive accumulation) of any vitamin contained in the formulation.
• Known hypersensitivity or allergy to Cernevit, its active ingredients (especially Vitamin B1), or excipients, including soy or peanut proteins/products (as the lecithin in the formulation is soy-derived).

Restrictions and Special Considerations

Population Category	Eligibility Status & Constraint
Children under 11 years	Not recommended. Safety and efficacy are not established, and the formulation is inadequate for this age group (lacks Vitamin K, insufficient Vitamin D).
Breast-feeding Women	Use is not recommended due to the risk of Vitamin A overdose in the neonate.
Hepatic or Renal Impairment	Requires careful monitoring to prevent Vitamin A and D toxicity, particularly in patients with cholestasis or liver disease, who have increased susceptibility to Vitamin A toxicity.
Additional Vitamin Use	Requires monitoring of blood vitamin levels, especially Vitamins A, D, and E, to avoid overdose.

Physicians must carefully consider the potential risks and benefits for each patient, especially when a risk of hypervitaminosis exists.

Cernevit is a multivitamin preparation whose components can participate in various officially documented interaction patterns with other medicines and products.

---

Drug-Drug Interactions

Co-administration of the Pyridoxine (Vitamin B6) component may reduce the therapeutic effect of Levodopa, a pharmacodynamic interaction noted to be less relevant when Levodopa is combined with a peripheral decarboxylase inhibitor. The Folic acid (Vitamin B9) component may increase the metabolic clearance of certain antiepileptic medicines (such as phenytoin, phenobarbital, and primidone), resulting in a reduction in their plasma concentration. Furthermore, the Vitamin E component may contribute to an additive risk of bleeding when combined with Coumarin derivatives (oral anticoagulants). The antibiotic Chloramphenicol may also interfere with the haematological response to the Cyanocobalamin (Vitamin B12) component.

---

Product and Administration Restrictions

An official restriction exists against co-administration with other high-dose Vitamin A supplements due to the risk of additive accumulation, potentially leading to Hypervitaminosis A. For technical administration reasons, Cernevit must not be mixed with solutions containing reducing agents (e.g., sodium metabisulphite), as this causes chemical degradation of vitamins like Thiamine (Vitamin B1). Patients with severe hepatic impairment or cholestasis face a population-specific risk of Retinol accumulation due to impaired clearance.

The Mechanisms of Action for Cernevit

Cofactor Replenishment for Cellular Energetics

Cernevit acts primarily through the direct delivery of metabolic cofactors. The B-vitamins, including Thiamine ( B1), function as essential enzyme partners for catalytic reactions in the TCA cycle and macronutrient processing. Cofactor binding re-enables the catalytic activity of these enzymes, which regulates ATP synthesis in all cells, including the Central Nervous System.

---

Antioxidant Synergy and Cell Structure Protection

A second major mechanism involves the coordinated redox activity of antioxidant vitamins. Ascorbic Acid ( C) and DL-alpha-Tocopherol ( E) neutralize free radicals throughout the body. The mechanism is synergistic: Vitamin C chemically regenerates the oxidized form of Vitamin E, thereby preserving the integrity of the cell membrane's lipid bilayer from lipid peroxidation.

---

Mechanisms of DNA Synthesis and Cell Maturation

The final core mechanism addresses cellular renewal. Folate ( B9) and Cobalamin ( B12) are essential cofactors for the one-carbon unit transfer required for DNA and RNA synthesis. The replenishment of these cofactors influences the efficiency of DNA synthesis and the subsequent maturation of cells with high turnover, such as those in the bone marrow. Concurrently, Retinol ( A) metabolites bind to nuclear receptors to regulate the gene transcription associated with epithelial cell differentiation.

How to Use Cernevit — Administration Guidelines

Cernevit is a formulation of multiple vitamins provided as a sterile, lyophilized powder that must be used strictly according to established instructions for administration.

---

Administration Scope

Administration Detail	Instruction
Route of Administration	Exclusively Intravenous (IV). Must be given either as a slow injection or an infusion.
Standard Dosing	The standard daily dose for adults and children 11 years is the contents of one vial per day.
Dosing Schedule	Administered once daily. Continuous use is standard throughout the period of parenteral nutrition.
Age-Group Rules	Not recommended for children under 11 years of age due to inappropriate vitamin concentrations for their specific total parenteral nutrition (TPN) needs.

---

Preparation and Procedural Steps

Cernevit requires mandatory preparation before use. The powder must be reconstituted by adding 5 mL of a compatible solvent, such as Sterile Water for Injection, 0.9% Sodium Chloride, or 5% Glucose solution.

• Reconstitution: Add 5 mL of the chosen solvent to the vial and gently mix until the powder is fully dissolved, resulting in a clear, yellow-orange solution.
• Administration Time: The reconstituted solution must be administered slowly over at least 10 minutes if given as an IV injection. Alternatively, it can be further diluted for continuous infusion.
• Handling Restriction: Any unused portion of the reconstituted solution must be immediately discarded. The product must be administered immediately or within 24 hours if stored under refrigeration.

Research Evidence and Overview of Studies for Cernevit

Evidence for Use in Vitamin Supplementation During Parenteral Nutrition (PN)

Research has examined Cernevit as a part of comprehensive parenteral nutrition (PN) regimens. These studies are relevant in trials assessing short-term or episodic symptom patterns, typically conducted during acute care settings, such as hospitalizations or stays in the Intensive Care Unit (ICU). The research has primarily explored outcomes related to systemic or functional imbalance, particularly in patients who cannot receive adequate nutrition through the digestive system. Short-term Randomized Controlled Trials (RCTs) and observational settings evaluating daily-life functioning have monitored patients with nutritional deficits due to major surgery, severe illness, or trauma.

The main focus of these studies has been on biochemical measurements. Researchers observed how the multivitamin supplementation was associated with the maintenance or changes in blood/serum levels of individual vitamins, such as Vitamin A, B-group vitamins, and Vitamin C. Studies monitored measured concentrations of vitamins in participants' plasma, and reported levels within the established reference range for many vitamins during the observed period. However, many trials research explored short-term symptom changes within the context of the overall PN mixture, and research examined the multivitamin within the overall PN regimen, limiting differentiation of the specific component's contribution.

Comparative Studies and Alternative Regimens

Studies have evaluated Cernevit against different nutritional strategies, including comparison to a placebo or other injectable multivitamin products. These comparisons were used in research exploring short-term symptom changes related to nutritional status, where the study examined differences in how vitamin levels were measured between the groups over defined time intervals. Findings indicate that while different regimens was associated with similar short-term outcomes related to vitamin concentration, the specific protocols and doses data show patterns related to measured individual vitamin status markers.

Long-Term Monitoring and Durability of Vitamin Status

The evidence contributes to the broader evidence landscape primarily regarding short-term use, generally covering a few weeks of treatment during acute episodes. Studies monitoring patients on longer-term PN regimens have examined vitamin levels over several weeks or months. Research highlights changes measured during the study period related to the ongoing maintenance of vitamin status. However, long-term effects are not fully established, and there is limited information for long-term outcomes regarding the durability of the vitamin status after a patient transitions off the intravenous supplement.

Evidence in Specific Patient Populations

Research studies monitored various populations, including critically ill adults. The research so far indicates patterns of vitamin level management for these groups. However, the evidence data for certain groups remain insufficient and requires careful consideration of individual patient needs.

Subgroup Analysis in Adult and Older Adult Patients

Adults and older adults are the most frequently evaluated in the available research. Studies monitored the vitamin status in these patients during their course of PN. Findings describe patterns observed in the studies related to achieving and maintaining specific vitamin levels. Data show patterns related to the need for ongoing monitoring, especially in patients with conditions marked by functional limitations such as kidney or liver challenges, where specific monitoring considerations were highlighted in the research.

Research Status in Pediatric Populations (Under 11)

Research was studied for multivitamin products in very young children, but the evidence for Cernevit specifically in children under 11 years of age is limited. The research population included adults and children 11 years and above.

What the Research Still Needs to Clarify (Evidence Gaps)

Several key areas remain uncertain regarding the research evidence for Cernevit. Comparative evidence is lacking for many direct, head-to-head trials against all alternatives, especially when looking at long-term outcomes. Sample sizes were modest in some of the specific studies, meaning the results apply only to the populations studied and research does not determine whether an individual will respond similarly.

Information for long-term clinical outcomes that go beyond biochemical levels is limited, as follow-up durations were limited in many of the core trials. Research is ongoing to provide context but evidence is limited when exploring factors like patient-reported outcomes describing perceived discomfort after prolonged use. These limitations mean evidence highlights what is known — and what is still uncertain — about the full scope of use.

How to Store and Dispose of Cernevit

The storage and disposal of Cernevit must adhere strictly to official regulatory guidelines to maintain product integrity and ensure proper handling.

Unreconstituted Powder Storage

• The unopened vial must be stored at a temperature not exceeding 25°C (77°F).
• The powder must be protected from light and heat and must not be frozen.
• Keep the vial in its outer carton to protect it from light and out of the sight and reach of children.

Reconstituted Solution Stability

Once the powder is reconstituted, the solution should be used immediately. If immediate use is not possible, the solution may be stored under refrigeration (mathbf2 C to mathbf8 C) for a maximum period of 24 hours.

Disposal Requirements

Cernevit is for single use only. Any unused portion of the reconstituted solution must be discarded. Disposal of the unused or expired product must be done in accordance with local requirements for pharmaceutical products.